The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20060940: Mr. William J. McEnery; Isle of Capri Casinos, Inc.
20060927: Macquarie Infrastructure Company Trust; Loving Enterprises, Inc.
20060919: SAP AG; Virsa Systems, Inc.
20060887: Fisher Scientific International Inc.; Clintrak Pharmaceutical Services, LLC
20060871: Linsalata Capital Partners Fund IV, L.P.; W. Randall Holloway
0604015 Informal Interpretation
0604018 Informal Interpretation
20060974: CHS Private Equity V LP; Allied Capital Corporation
20060967: Nautic Partners V, L.P.; Craig Meyers and Francine Meyers
20060966: Nautic Partners V, L.P.; Paul & Pamela Roy
20060957: President and Fellows of Harvard College; Sempra Energy
20060955: Pogo Producing Company; Warburg Pincus Private Equity VIII
20060939: Cerberus FIM Investors, LLC; General Motors Corporation
0604017 Informal Interpretation
Allergan, Inc., and Inamed Corporation, In the Matter of
The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.